Your shopping cart is currently empty

FASN-IN-7 is a potent inhibitor of human fatty acid synthase (FASN). It effectively inhibits both the full-length FASN and the FASN KR domain, with IC50 values of 28 nM and 54 nM, respectively. FASN-IN-7 is capable of significantly suppressing the proliferation of various cancer cells. Additionally, it can increase the levels of malonyl-CoA in tumor tissues while reducing palmitic acid levels.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | FASN-IN-7 is a potent inhibitor of human fatty acid synthase (FASN). It effectively inhibits both the full-length FASN and the FASN KR domain, with IC50 values of 28 nM and 54 nM, respectively. FASN-IN-7 is capable of significantly suppressing the proliferation of various cancer cells. Additionally, it can increase the levels of malonyl-CoA in tumor tissues while reducing palmitic acid levels. |
| In vitro | FASN-IN-7 (Compound 34) exhibits potent inhibition of cell proliferation within LRS, impacting various cancer cell lines such as A2780 (ovarian cancer), PC3M (prostate cancer), LNCaP (prostate cancer), OCI-LY1 (lymphoma), MV4-11 (leukemia/lymphoma/myeloma), H460 (lung cancer), A549 (lung cancer), and MDA-MB-468 (breast cancer), with EC50 values of 13, 25, 66, 55, 59, 36, 20, and 26 nM, respectively. |
| In vivo | Administered orally at doses ranging from 3 to 30 mg/kg twice daily for two days, FASN-IN-7 increases the malonyl-CoA concentration while decreasing palmitic acid levels in mice with NCI-H460 lung xenograft tumors. |
| Molecular Weight | 493.61 |
| Formula | C30H31N5O2 |
| Cas No. | 1579514-16-1 |
| Smiles | O=C1C2(N=C(N1C[C@H]3CN(C(=O)C4CC4)CC3)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CN(C)N=C7)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.